Form 4: Opus Genetics Director, Adrienne L. Graves, Receives Stock and Options Grant

Director Adrienne L. Graves received a grant of restricted stock units and stock options from Opus Genetics, Inc. on April 30, 2025.

Summary

• On April 30, 2025, Adrienne L. Graves, a director of Opus Genetics, Inc., was granted 79,504 shares of common stock and options to purchase 79,592 shares.
• The common stock was received as restricted stock units.
• The exercise price for the stock options is $0.95 per share.
• Both the restricted stock units and the options vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, contingent upon continued service.
• Following the transaction, Graves beneficially owns 79,504 shares of common stock and options to purchase 79,592 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. The grant itself is a positive event for the recipient.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Grants of stock and options to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders. The specific terms of the grant, such as the vesting schedule and exercise price, are typical for this type of compensation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• Companies like Regeneron and Amgen also use stock options and restricted stock units as part of their director compensation packages.
• The vesting schedule of one year or until the next annual meeting is fairly standard, aligning with typical industry practices.
• The exercise price of $0.95 is specific to Opus Genetics and its stock valuation.

Stakeholder Impact

• The grant of stock and options could positively impact shareholders by aligning the director's interests with the company's long-term success.
• The director benefits from the potential increase in the value of the stock and options.

Key Dates

Keywords

Opus Genetics, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, IRD